cliffwatch

meloxicam; rizatriptan benzoate · Axsome · NDA 215431

Symbravo

Earliest generic entry, as listed
10 Mar 2045

Blocked by patent: US 12544383. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 96 unexpired

PatentClaimsExpires
US 12544383use U-171910 Mar 2045
US 12005118use U-171925 Jan 2043
US 12370196use U-171929 Dec 2041
US 12611413use U-171929 Dec 2041
US 12128052use U-171928 May 2040
US 12551488use U-171928 May 2040
US 12551489use U-171928 May 2040
US 12685736use U-17199 May 2040
US 12472256use U-435618 May 2038
US 12472257use U-413418 May 2038
US 12472258product18 May 2038
US 12616752use U-451018 May 2038
US 10029010use U-413311 Apr 2036
US 10058614product11 Apr 2036
US 10137131product, use U-171911 Apr 2036
US 10195278use U-171911 Apr 2036
US 10265324use U-171911 Apr 2036
US 10265399use U-450911 Apr 2036
US 10265400use U-450911 Apr 2036
US 10307484use U-450911 Apr 2036
US 10363312use U-171911 Apr 2036
US 10369224use U-413411 Apr 2036
US 10369225use U-435611 Apr 2036
US 10426839use U-413511 Apr 2036
US 10456471use U-450911 Apr 2036
US 10463736product11 Apr 2036
US 10471014use U-171911 Apr 2036
US 10471069use U-171911 Apr 2036
US 10512692use U-171911 Apr 2036
US 10512693use U-171911 Apr 2036
US 10517950use U-171911 Apr 2036
US 10532101use U-171911 Apr 2036
US 10537642use U-171911 Apr 2036
US 10561664use U-171911 Apr 2036
US 10583144use U-171911 Apr 2036
US 10653777use U-171911 Apr 2036
US 10688102use U-171911 Apr 2036
US 10688185use U-171911 Apr 2036
US 10695429use U-171911 Apr 2036
US 10695430use U-171911 Apr 2036
US 10702535use U-413611 Apr 2036
US 10702602use U-171911 Apr 2036
US 10722583use U-171911 Apr 2036
US 10729696use U-171911 Apr 2036
US 10729697use U-171911 Apr 2036
US 10729773use U-171911 Apr 2036
US 10758617use U-171911 Apr 2036
US 10758618use U-171911 Apr 2036
US 10780165use U-171911 Apr 2036
US 10780166use U-171911 Apr 2036
US 10799588use U-171911 Apr 2036
US 10821181use U-171911 Apr 2036
US 10821182use U-171911 Apr 2036
US 10894053use U-171911 Apr 2036
US 10905693use U-171911 Apr 2036
US 10918722use U-171911 Apr 2036
US 10933136use U-171911 Apr 2036
US 10933137use U-171911 Apr 2036
US 10940153use U-171911 Apr 2036
US 10987358use U-171911 Apr 2036
US 11013805use U-171911 Apr 2036
US 11013806use U-171911 Apr 2036
US 11020483use U-171911 Apr 2036
US 11045549use U-171911 Apr 2036
US 11135295use U-171911 Apr 2036
US 11207328use U-171911 Apr 2036
US 11219626use U-171911 Apr 2036
US 11266657use U-171911 Apr 2036
US 11285213use U-171911 Apr 2036
US 11331323use U-171911 Apr 2036
US 11369684use U-171911 Apr 2036
US 11426414use U-171911 Apr 2036
US 11433078use U-171911 Apr 2036
US 11433079use U-171911 Apr 2036
US 11471464use U-171911 Apr 2036
US 11471465use U-171911 Apr 2036
US 11504429use U-171911 Apr 2036
US 11510927use U-171911 Apr 2036
US 11571428use U-171911 Apr 2036
US 11602563use U-171911 Apr 2036
US 11607456use U-171911 Apr 2036
US 11617755use U-171911 Apr 2036
US 11617756use U-171911 Apr 2036
US 11617791use U-171911 Apr 2036
US 11628173use U-171911 Apr 2036
US 11712441use U-171911 Apr 2036
US 11738085use U-171911 Apr 2036
US 11759522use U-171911 Apr 2036
US 11801250use U-171911 Apr 2036
US 11806354use U-171911 Apr 2036
US 11826370use U-171911 Apr 2036
US 11865117use U-171911 Apr 2036
US 11944683use U-171911 Apr 2036
US 12485176use U-413311 Apr 2036
US 12691123use U-171911 Apr 2036
US 9821075product, use U-171911 Apr 2036

Exclusivities · 1 unexpired

NPnew product30 Jan 2028

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
215431 · 001 · RLDtablet, oral20MG;EQ 10MG BASE10 Mar 2045